OakChart

Revelation Biosciences Inc

REVBHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 2:11 PM ET

4.35+0.41 (10.41%)
2026-11-11 20:11 CET
Market cap
2.69 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-17.84 USD m
Free cash flow, TTM
-10.21 USD m
EPS diluted, TTM
-42.50
P/E
-
Compare

Price

REVB against its 20, 50 and 200-day averages
2050200earnings
10.0020.0030.0078K157KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26REVBclose 4.3520-day 3.9050-day 5.27200-day 7.454.35

89.3% under the 52-week high of 40.60 on 23 Jan 2026. 52-week low 3.08 on 19 Oct 2026. Last 15 sessions, 41.4% high to low

Profile

REVB
52-week range, 3% of the way up
3.0840.60

Revelation Biosciences, Inc. engages in the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

Employees8
IPONov 17, 2020
Beta-0.12
ATR, 14d0.47
Rel volume1.22
Short float2.84%
Inst own6.36%

Snapshot

6 groups

Valuation

Index-
Market Cap2.97M
Enterprise Value-5.34M
Income-17.84M
Sales0.00M
Book/sh10.58
Cash/sh13.36
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPONov 17, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.41
P/C0.33
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.98
Current Ratio3.98
Debt/Eq0.11
LT Debt/Eq0.06
Option/ShortNo / Yes

Earnings

EPS (ttm)-42.50
EPS next Y-10.91
EPS next Q-5.36
EPS this Y79.07%
EPS next Y68.90%
EPS next 5Y68.54%
EPS past 3/5Y94.09% 76.86%
Sales past 3/5Y- -
EPS Y/Y TTM94.95%
Sales Y/Y TTM-
EPS Q/Q88.03%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.3.90% -

Ownership

Insider Own-
Insider Trans-
Inst Own6.36%
Inst Trans-
ROA-106.29%
ROE-133.35%
ROIC-158.02%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2011.47%
SMA50-17.47%
SMA200-41.63%
Trades-

Technical

Shs Outstand0.68M
Shs Float0.45M
Short Float2.84%
Short Ratio1.06
Short Interest0.01M
52W High40.60 -89.29%
52W Low3.08 41.23%
Volatility12.97% 12.56%
ATR (14)0.47
RSI (14)49.27
Beta-0.12
Rel Volume1.22
Avg Volume12.10K
Volume10,803

Performance

Perf Week5.64%
Perf Month-14.90%
Perf Quarter-44.02%
Perf Half Y-40.82%
Perf YTD-80.58%
Perf Year-84.46%
Perf 3Y-99.98%
Perf 5Y-100.00%
Perf 10Y-
Recom1.00
Target Price124.25
Prev Close3.94
Price4.35
Change %10.41%

Peers

Mkt cap
TickerCompanyMkt cap
ICUSeaStar Medical Holding Corp9.94M
XRTXXORTX Therapeutics Inc1.52M
CALCCalciMedica Inc8.74M
ENLVEnlivex Ltd1.88M
IFRXInflaRx NV174.64M
AKTXAkari Therapeutics Plc ADR13.10M
UNCYUnicycive Therapeutics Inc104.18M
CMMBChemomab Therapeutics Ltd ADR9.64M
CVKDCadrenal Therapeutics Inc5.00M
CTXRCitius Pharmaceuticals Inc13.53M

News

latest 14 of 200
  • Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 (Business Wire) -13.54% +9.27%
  • Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 (Business Wire) -36.41%
  • Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study (Business Wire)
  • Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 (ACCESSWIRE)
  • Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury (ACCESSWIRE) +7.37%
  • Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE)
  • Revelation Biosciences Announces Adoption of Stockholder Rights Plan (ACCESSWIRE)
  • Revelation Biosciences Expands Acute Kidney Injury Advisory Board (ACCESSWIRE)
  • Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders (ACCESSWIRE)
  • Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 (ACCESSWIRE) -5.88%
  • Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board (ACCESSWIRE) -7.20%
  • Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study (ACCESSWIRE) +5.31%
  • Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference (ACCESSWIRE)
  • Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 (ACCESSWIRE) -5.67%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-5.920-6.160-0.000.002
2026Q22026-08-06-6.090-6.125-6.0750.000.002
2026Q12026-05-07-18.970-18.970-18.9650.000.002
2025Q42026-02-26-11.550-25.620-11.5340.000.002
2025Q32025-11-06-49.560-37.380-49.5150.000.002
2025Q22025-08-08-196.28-77.280-196.260.000.001
2025Q12025-05-08-177.24-577.92-177.380.000.002
2024Q42025-03-06-418.32-866.88-418.350.000.002
2024Q32024-11-08-1,129-3,817-1,1240.000.002
2024Q22024-08-09-6,895-2,426-6,8960.000.002
2024Q12024-05-10-3,306-7,237-3,3070.000.002
2023Q42024-03-22-11,196-18,325-11,1920.000.002
2023Q32023-11-13-16,934-13,507-16,8290.000.002
2023Q22023-08-11-10,080-13,104-10,0460.000.002
2023Q12023-05-22112,493-26,20879,1920.000.001
2022Q42023-03-30-71,366-70,560-71,2940.000.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-1,651,104-1,255,968-1,713,6200.000.00
2022FY-810,029-823,334-810,0430.00-0.57
2023FY-712.32-41,167-706.810.000.00
2024FY-7,365-10,053-7,3650.000.00
2025FY-167.65-256.2-0.000.00
2026FY--35.085--0.00
2027FY--10.910--0.00
2028FY--5.220---
2029FY-6.170--43.79
2030FY-14.460--101.38

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-062000.000.000.00
2026Q4S2026-08-072000.000.000.00
2026Q4S2026-05-112000.000.000.00
2026Q4S2026-02-272000.000.000.00
2026Q4S2026-01-151000.000.000.00
2026Q4E2026-11-06210-5.36-5.39-5.33
2026Q4E2026-10-21200-5.99-6.58-5.39
2026Q4E2026-10-19210-5.99-6.58-5.39
2026Q4E2026-08-07211-5.99-6.58-5.39
2026Q4E2026-08-05201-6.02-6.58-5.46
2026Q4E2026-07-22200-5.50-5.53-5.46
2026Q4E2026-07-20210-5.50-5.53-5.46
2026Q4E2026-05-11211-5.50-5.53-5.46
2026Q4E2026-05-08211-5.50-5.53-5.46

Estimate history

EPS, annual-564.48-252915.264-1713620.16-810042.912-706.81-7365.389-167.62-42.4985
Period2019202020212022202320242025TTM
EPS, quarterly-1124.149-418.347-177.379-196.261-49.515-11.534-18.965-6.075-5.925
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual000000.0060.2260.683
Period2019202020212022202320242025MRQ
Shares, quarterly0.0030.0060.0110.0550.1280.2260.5580.5580.683
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.030.030.040.070.000.00
Gross Profit-0.03-0.03-0.03-0.03-0.04-0.070.000.00
Selling, General and Administrative Excl. Other12.689.047.958.6310.8211.880.150.00
Research and Development5.774.063.554.155.386.91--
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.71-9.07-7.98-8.66-10.86-11.95-0.15-0.00
Interest Expense0.000.000.000.00-0.040.000.00
Unusual Expense-0.00-0.00-0.08-8.330.000.001.500.00
Net Income Before Taxes-12.16-8.91-15.04-0.12-10.83-11.99-1.63-0.00
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-12.16-8.91-15.04-0.12-10.83-11.99-1.63-0.00
Net Income From Continuing Operations-12.16-8.91-15.04-0.12-10.83-11.99-1.63-0.00
Net Income-17.84-14.87-15.04-0.12-10.83-11.99-1.63-0.00
EPS (Recurring)-31.88-167.64-7,393.31-34,978.00-810,038.77-1,713,624.26-90,487.64-564.31
EPS (Basic, Before Extraordinaries)-42.50-167.62-7,365.39-706.81-810,042.91-1,713,620.16-252,915.26-564.48
EPS (Diluted)-42.50-167.62-7,365.39-706.81-810,042.91-1,713,620.16-252,915.26-564.48
EBITDA-12.68-9.04-7.95-8.63-10.82-11.88-0.15-0.00
Non-Operating Income (Expense)0.550.16-7.140.210.03-0.040.010.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.720.600.170.160.300.47--
Price To Earnings Ratio-----37.56--
Shares Outstanding0.680.230.010.000.000.000.000.00
Market Capitalization2.692.693.853.154.4766.8591.4370.14

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.010.010.010.01
Gross Profit-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other3.383.653.092.571.942.452.091.75
Research and Development1.511.921.380.960.921.320.860.61
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.38-3.66-3.09-2.57-1.94-2.46-2.09-1.75
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.00-0.00-0.00-0.00-0.00-0.00
Net Income Before Taxes-3.32-3.32-3.01-2.51-1.91-2.44-2.05-1.73
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.32-3.32-3.01-2.51-1.91-2.44-2.05-1.73
Net Income From Continuing Operations-3.32-3.32-3.01-2.51-1.91-2.44-2.05-1.73
Net Income-3.32-3.32-8.69-2.51-4.68-5.63-2.05-1.73
EPS (Recurring)-5.92-6.08-18.97-11.53-49.52-196.26-177.47-418.79
EPS (Basic, Before Extraordinaries)-5.92-6.08-18.97-11.53-49.51-196.26-177.38-418.35
EPS (Diluted)-5.92-6.08-18.97-11.53-49.51-196.26-177.38-418.35
EBITDA-3.38-3.65-3.09-2.57-1.94-2.45-2.09-1.75
Non-Operating Income (Expense)0.070.340.080.060.040.020.040.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.480.400.470.370.000.000.220.07
Shares Outstanding0.680.560.560.230.130.050.010.01
Market Capitalization2.694.034.695.075.093.452.533.85

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments10.706.5011.995.251.270.540.00
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.110.070.080.070.640.110.00
Total Current Assets10.816.5712.085.331.910.650.00
Net Property, Plant & Equipment0.740.060.070.090.130.000.00
Total Investments and Advances0.000.000.000.000.0073.510.00
Intangible Assets-0.000.000.000.000.000.00
Other Assets0.030.000.070.090.000.000.02
Total Assets11.586.6212.215.502.0474.160.02
Short Term Debt Incl. Current Port. of LT Debt0.020.000.000.000.020.000.00
Accounts Payable0.580.781.360.550.600.000.00
Other Current Liabilities1.401.134.203.901.533.430.03
Total Current Liabilities2.001.915.564.452.143.430.03
Long Term Debt0.720.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.002.910.00
Total Liabilities2.721.915.564.452.146.340.03
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity8.864.716.651.05-0.1067.82-0.00
Total Shareholders Equity8.864.716.651.05-0.1067.82-0.00
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity8.864.716.651.05-0.1067.82-0.00
Total Liabilities & Stockholders Equity11.586.6212.215.502.0474.160.02
Book Value Per Share39.16757.3527,848.5062,139.97-14,219.9110,519,569.17-564.31
Tangible Book Value Per Share39.16757.3527,848.5062,139.97-14,219.9110,519,561.08-564.31
Full-Time Employees8996142-
Price to Book Ratio0.370.820.362.011.671.355,474.13
Return on Assets-97.93-159.69-1.36-40.19-31.46-4.40-
Return on Equity-131.38-264.85-3.12-52.77-35.40-4.81-
Return on Invested Capital-93.00-319.40-1.81-1,028.98--2.40-
Quick Ratio5.413.432.171.200.890.190.00
Current Ratio5.413.432.171.200.890.190.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-12.16-8.91-15.04-0.12-10.83-11.99-1.63-0.00
Depreciation0.030.030.030.030.040.07--
Other Funds (Non Cash)1.910.620.11-8.170.300.471.500.00
Funds from Operations-10.22-8.26-14.90-8.27-10.49-11.45-0.13-0.00
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital0.12-0.01-3.420.98-0.730.36-0.080.00
Cash from Operating Activities-10.10-8.27-18.32-7.29-11.22-11.09-0.220.00
Capital Expenditures-0.110.00-0.020.000.00-0.130.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00-74.040.00
Purchase of Investments0.000.000.000.000.000.00-74.040.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.110.00-0.020.000.00-0.13-74.040.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock6.6212.4712.8514.0315.998.0074.25-0.01
Repurchase of Common Pref Stock0.000.000.00-0.01-7.650.000.000.00
Sale of Common Pref Stock6.6212.4712.8514.0323.658.0074.25-0.01
Proceedsfrom Stock Options0.003.395.4214.0323.648.0074.25-0.01
Issuance or Reduction of Debt, Net0.000.000.000.00-0.800.000.010.00
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.01
Other Financing Activities Uses0.000.000.000.000.000.000.00-
Cash from Financing Activities6.6212.4712.8514.0315.208.0074.260.00
Net Change in Cash-3.594.20-5.496.743.98-3.220.010.00
Free Cash Flow-10.21-8.27-18.34-7.29-11.22-11.22-0.220.00
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments9.1211.4814.1110.7012.715.17
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.150.200.090.110.120.19
Total Current Assets9.2711.6814.2110.8112.835.36
Net Property, Plant & Equipment0.720.780.810.740.020.04
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets----0.000.00
Other Assets0.030.030.030.030.000.00
Total Assets10.0212.5015.0411.5812.865.40
Short Term Debt Incl. Current Port. of LT Debt0.340.190.120.020.000.00
Accounts Payable1.070.930.830.581.030.83
Other Current Liabilities0.920.760.471.400.820.74
Total Current Liabilities2.331.881.422.001.851.57
Long Term Debt0.460.550.640.720.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.792.432.062.721.851.57
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity7.2310.0712.998.8611.003.83
Total Shareholders Equity7.2310.0712.998.8611.003.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity7.2310.0712.998.8611.003.83
Total Liabilities & Stockholders Equity10.0212.5015.0411.5812.865.40
Book Value Per Share10.5818.0323.2639.1685.9069.80
Tangible Book Value Per Share10.5818.0323.2639.1685.9069.80
Full-Time Employees---8--
Price to Book Ratio0.370.400.360.570.460.90
Return on Assets-106.29-120.17-103.83-97.93-82.96-95.82
Return on Equity-133.35-154.77-124.41-131.38-118.88-340.81
Return on Invested Capital-43.09-31.30-22.08-26.20-17.34-63.89
Quick Ratio3.986.2110.025.416.923.42
Current Ratio3.986.2110.025.416.923.42

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-3.32-3.32-3.01-2.51-1.91-2.44
Depreciation0.010.010.010.010.010.01
Other Funds (Non Cash)0.530.460.530.390.000.00
Funds from Operations-2.77-2.86-2.48-2.12-1.90-2.44
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.410.30-0.740.150.310.52
Cash from Operating Activities-2.36-2.56-3.21-1.97-1.59-1.92
Capital Expenditures0.00-0.04-0.070.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.04-0.070.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock0.00-0.036.70-0.049.123.39
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.00-0.036.70-0.049.123.39
Proceedsfrom Stock Options0.000.000.000.003.390.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.00-0.036.70-0.049.123.39
Net Change in Cash-2.36-2.633.41-2.017.531.47
Free Cash Flow-2.36-2.60-3.29-1.97-1.59-1.92

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.84%0.0M0.5M10.79K
2026-10-150.21%0.0M0.5M5.27K
2026-09-300.05%0.0M0.4M5.64K
2026-09-150.01%0.0M0.4M5.70K
2026-08-310.02%0.0M0.4M6.52K
2026-08-140.49%0.0M0.4M5.96K
2026-07-310.54%0.0M0.5M7.32K
2026-07-150.54%0.0M0.5M8.59K
2026-06-300.37%0.0M0.5M8.90K
2026-06-150.50%0.0M0.5M9.69K
2026-05-290.73%0.0M0.5M10.40K
2026-05-150.96%0.0M0.5M12.23K
2026-04-300.51%0.0M0.5M19.01K
2026-04-150.64%0.0M0.5M95.66K
2026-03-313.37%0.0M0.2M94.67K
2026-03-131.62%0.0M0.2M93.20K
2026-02-270.80%0.0M0.2M90.57K
2026-02-1314.30%0.0M0.1M88.63K
2026-01-3024.36%0.0M0.2M80.77K
2026-01-150.69%0.0M0.1M4.05K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-08-198-KCurrent report2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-138-A12BSEC
2026-07-138-KCurrent report2026-07-10SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-06-018-KCurrent report2026-06-01SEC
2026-05-15SCHEDULE 13GSEC
2026-05-11ARSAnnual report to security holders. 2026-05-11SEC
2026-05-11DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-24SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-014Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-05-014Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-04-30PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-24SEC
2026-04-15S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-198-KCurrent report2026-03-18SEC
2026-02-268-KCurrent report2025-11-06SEC
2026-02-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-17DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-02-14SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-11EFFECTEffectiveness filing by commission orderSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
SABBY MANAGEMENT, LLC5.39%
CITADEL ADVISORS LLC0.99%
HRT FINANCIAL LP0.43%
GEODE CAPITAL MANAGEMENT, LLC0.43%
VANGUARD FIDUCIARY TRUST CO0.34%
UBS Group AG0.33%
Tower Research Capital LLC0.17%
ROYAL BANK OF CANADA0.02%
SBI Securities Co., Ltd.0.01%
BARCLAYS PLC0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.42%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. REVB. Cached 15 minutes.

Some panels did not load: ratings, insider.